Stephen P Mulligan
Overview
Explore the profile of Stephen P Mulligan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
2175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Lew T, Bennett R, Lin V, Whitechurch A, Handunnetti S, Marlton P, et al.
Blood Adv
. 2024 Jan;
8(6):1439-1443.
PMID: 38231032
No abstract available.
3.
Fatima N, Shen Y, Crassini K, Burling O, Thurgood L, Iwanowicz E, et al.
Leuk Lymphoma
. 2024 Jan;
65(5):585-597.
PMID: 38227293
Despite advances in treatment, a significant proportion of patients with chronic lymphocytic leukemia (CLL) will relapse with drug-resistant disease. The imipridones, ONC-201 and ONC-212, are effective against a range of...
4.
Anderson M, Bennett R, Badoux X, Best G, Chia N, Cochrane T, et al.
Intern Med J
. 2023 Sep;
53(9):1678-1691.
PMID: 37743239
Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in Australia and New Zealand (ANZ). Considerable changes to diagnostic and management algorithms have occurred within the last decade. The...
5.
Shen Y, Freeman J, Kerridge I, Downe P, Naidu K, Holland J, et al.
Br J Haematol
. 2023 Sep;
204(2):487-491.
PMID: 37669920
We analysed COVID-19 infection outcomes of 129/241 chronic lymphocytic leukaemia (CLL) (53.9%) and 22/55 monoclonal B-lymphocytosis (MBL) (40.0%) patients following multiple vaccine doses aiming for maximum measured anti-spike antibody response....
6.
7.
Lai B, Shen Y, Guminski A, Shumack S, Mulligan S
Australas J Dermatol
. 2023 Feb;
64(2):291-295.
PMID: 36721350
No abstract available.
8.
Bonfiglio S, Sutton L, Ljungstrom V, Capasso A, Pandzic T, Westrom S, et al.
Blood Adv
. 2023 Jan;
7(12):2794-2806.
PMID: 36696464
Patients with chronic lymphocytic leukemia (CLL) progressing on ibrutinib constitute an unmet need. Though Bruton tyrosine kinase (BTK) and PLCG2 mutations are associated with ibrutinib resistance, their frequency and relevance...
9.
Mulligan S, Opat S, Cheah C, Kuss B, Hertzberg M, Marlton P, et al.
Leuk Lymphoma
. 2022 Nov;
64(2):312-318.
PMID: 36423351
Ibrutinib is a small molecule inhibitor of Bruton's tyrosine kinase indicated for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL)....
10.
Shen Y, Freeman J, Holland J, Naidu K, Solterbeck A, Van Bilsen N, et al.
Blood
. 2022 Oct;
140(25):2709-2721.
PMID: 36206503
Patients with chronic lymphocytic leukemia (CLL) or monoclonal B-lymphocytosis (MBL) have impaired response to COVID-19 vaccination. A total of 258 patients (215 with CLL and 43 with MBL) had antispike...